AI주식인사이트AI Stock Insight
C

킵스파마

256940KOSDAQ

44.5 / 100

Reference Date: 2026-10-23

Financial Score16.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Declined 6.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Kipsis Pharma operates three main business segments: OLED equipment development and supply, battery recycling, and pharmaceutical manufacturing and sales. In the OLED segment, the company is expanding its global market through high-precision equipment and FMM mask development. The recycling segment produces lead ingots from recycled batteries for supply to battery manufacturers. Additionally, the biopharma segment is gaining growth momentum through the development of anticancer drugs and digital therapeutics.

Number of Employees

96people

Average Salary

55.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.38Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-14.33Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
77.31Industry Average 100.004.0Point

In line with industry avg

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲35.9% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲14.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.8% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 5,600Won52-week high 12,45052-week low 5,320
1-month return2.0Point

1m -6.04% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-16